~86% of patients experiencing dry eye disease (DED) have excessive tear evaporation due to MGD as the root cause3
Excessive tear evaporation is a direct consequence of MGD and a leading cause of DED signs and symptoms.4
MGD=meibomian gland dysfunction.
Not all treatments address evaporation in DED5-10
Associated with decreased quality of life and high economic burden, DED is a modern-day disorder in which digital lifestyle is a major contributor.10-12
If evaporation is not addressed, signs and symptoms of DED may chronically persist13
Examining DED with a focus on evaporation reveals a need to rethink current management approaches.
Review an expert perspective on DED written by ophthalmologist Darrell E. White, MD, the founder of SkyVision Centers.
NEW
Review an expert perspective on the mechanisms of DED written by optometrist Paul Karpecki, OD, FAAO, chief clinical editor for Review of Optometry.
SIGN UP
Sign up to stay informed about dry eye disease (DED), find out what your peers think about managing DED, and get updates about the advancements that Bausch + Lomb is pursuing.
References: 1. Kim M, Lee Y, Mehra D, Sabater AL, Galor A. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. 2021;6(1):e000697. doi:10.1136/bmjophth-2020-000697 2. Dunn JD, Karpecki PM, Meske ME, Reissman D. Evolving knowledge of the unmet needs in dry eye disease. Am J Manag Care. 2021;27(2 suppl):S23-S32. doi:10.37765/ajmc.2021.88625 3. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478. doi:10.1097/ICO.0b013e318225415a 4. Rabensteiner DF, Aminfar H, Boldin I, Schwantzer G, Horwath-Winter J. The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmol. 2018;96(6):e707-e711. doi:10.1111/aos.13732 5. Cequa. Prescribing information. Sun Pharmaceutical Industries, Inc; 2019. 6. Eysuvis. Prescribing information. Kala Pharmaceuticals; 2022. 7. Restasis. Prescribing information. Allergan; 2017. 8. Xiidra. Prescribing information. Novartis Pharmaceuticals Corporation; 2020. 9. Tyrvaya. Prescribing information. Oyster Point Pharmaceuticals; 2021. 10. Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409-415. doi:10.1016/j.ajo.2006.11.060 11. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379-387. doi:10.1097/ICO.0b013e3181f7f363 12. Al-Mohtaseb Z, Schachter S, Shen Lee B, Garlich J, Trattler W. The relationship between dry eye disease and digital screen use. Clin Ophthalmol. 2021;15:3811-3820. doi:10.2147/OPTH.S321591 13. Lienert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. Long-term natural history of dry eye disease from the patient's perspective. Ophthalmology. 2016;123(2):425-433. doi:10.1016/j.ophtha.2015.10.011
Follow Bausch + Lomb:
